Home    Back

Secukinumab 150 mg (2 injections per dose    (DrugBank: Secukinumab)

1 disease
IDDisease name (Link within this page)Number of trials
269Pyogenic arthritis1

269. Pyogenic arthritis    [ 20 clinical trials,   26 drugs,   (DrugBank: 10 drugs),   12 drug target genes,   90 drug target pathways]
Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 20 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04274166
(ClinicalTrials.gov)		January 202112/2/2020Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumThe Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumPyoderma GangrenosumDrug: secukinumab 150 mg (2 injections per doseWake Forest University Health SciencesNovartisNot yet recruiting18 Years75 YearsAll6Phase 2United States